Cargando…
How can a joint European health technology assessment provide an ‘additional benefit’ over the current standard of national assessments?: Insights generated from a multi-stakeholder survey in hematology/oncology
OBJECTIVES: We conducted a multi-stakeholder survey to determine key areas where a joint European health technology assessment (HTA) could provide ‘additional benefit’ compared to the status quo of many parallel independent national and subnational assessments. METHODS: Leveraging three iterative De...
Autores principales: | Julian, Elaine, Gianfrate, Fabrizio, Sola-Morales, Oriol, Mol, Peter, Bergmann, Jean-François, Salmonson, Tomas, Hebborn, Ansgar, Grande, Mathilde, Ruof, Jörg |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161501/ https://www.ncbi.nlm.nih.gov/pubmed/35652987 http://dx.doi.org/10.1186/s13561-022-00379-7 |
Ejemplares similares
-
Shaping a research agenda to ensure a successful European health technology assessment: insights generated during the inaugural convention of the European access academy
por: Julian, Elaine, et al.
Publicado: (2022) -
The role of stakeholder involvement in the evolving EU HTA process: Insights generated through the European Access Academy’s multi-stakeholder pre-convention questionnaire
por: Van Haesendonck, Lauren, et al.
Publicado: (2023) -
Leveraging EUnetHTA’s conceptual framework to compare HTA decision drivers in France, Italy, and Germany from a manufacturer’s point of view
por: Giuliani, Giovanni, et al.
Publicado: (2018) -
Early Benefit Assessments in Oncology in Germany: How Can a Clinically Relevant Endpoint Not Be Relevant to Patients?
por: Ruof, Jörg, et al.
Publicado: (2015) -
Perspectives to mitigate payer uncertainty in health technology assessment of novel oncology drugs
por: Solà-Morales, Oriol, et al.
Publicado: (2019)